Type 2 Diabetes Program in Medication Adherence and Persistence
P-MAPP’s inaugural program is collecting information from patients who are taking oral and/or injectable medications for Type 2 diabetes.
The following list contains all of the medications that qualify under the P-MAPP protocol. They are divided into four categories: required oral, required injectable, allowed oral and allowed injectable. As defined by the protocol, 40% of the patients must be taking the “required medications” and the remaining 60% can take the “allowed medications” or a combination of the two. Please click the icon by each drug category to view the specific required/allowed medications.
Medications
Required Injectable Medications
Adlyxin
Bydureon
Byetta
Ozempic
Soliqua
Trulicity
Victoza
Xultophy
Adlyxin
Bydureon
Byetta
Ozempic
Soliqua
Trulicity
Victoza
Xultophy
Required Oral Medications
Farxiga
Invokamet
Invokana
Jardiance
Segluromet
Steglatro
Synjardy
Xigduo XR
Farxiga
Invokamet
Invokana
Jardiance
Segluromet
Steglatro
Synjardy
Xigduo XR
Janumet
Januvia
Jentadueto
Kazano
Kombiglyze XR
Nesina
Onglyza
Oseni
Tradjenta
Glyxambi
Qtern
Allowed Injectable Medications
acarbose
Actoplus Met
Actoplus Met XR/ER/SR
Actos
Amaryl
Avandia
bromocriptine
colesevelam
Cycloset
DiaBeta
Duetact
Fortamet
glimepiride
Glipizide
Glipizide extended release
Glipizide plus metformin
Glipizide XL
Glucophage
Glucophage XR
Glucotrol
Glucotrol XL
Glucovance
Glumetza
glyburide (also known as glybenclamide)
glyburide micronized
glyburide plus metformin
Glynase
Glynase PresTab
Glyset
Metaglip
metformin
metformin liquid
metformin ER
metformin SR
Micronase
miglitol
nateglinide
pioglitazone
pioglitazone plus glimeperide
pioglitazone plus metformin
pioglitazone plus metformin, extended release
Piomet
Prandimet
Prandin
Basaglar
Humulin N
Lantus
Levemir
Novolin N
Toujeo
Tresiba
Allowed Oral Medications
acarbose
Actoplus Met
Actoplus Met XR/ER/SR
Actos
Amaryl
Avandia
bromocriptine
colesevelam
Cycloset
DiaBeta
Duetact
Fortamet
glimepiride
Glipizide
Glipizide extended release
Glipizide plus metformin
Glipizide XL
Glucophage
Glucophage XR
Glucotrol
Glucotrol XL
Glucovance
Glumetza
glyburide (also known as glybenclamide)
glyburide micronized
glyburide plus metformin
Glynase
Glynase PresTab
Glyset
Metaglip
metformin
metformin liquid
metformin ER
metformin SR
Micronase
miglitol
nateglinide
pioglitazone
pioglitazone plus glimeperide
pioglitazone plus metformin
pioglitazone plus metformin, extended release
Piomet
Prandimet
Prandin
acarbose
Actoplus Met
Actoplus Met XR/ER/SR
Actos
Amaryl
Avandia
bromocriptine
colesevelam
Cycloset
DiaBeta
Duetact
Fortamet
glimepiride
Glipizide
Glipizide extended release
Glipizide plus metformin
Glipizide XL
Glucophage
Glucophage XR
Glucotrol
Glucotrol XL
Glucovance
Glumetza
glyburide (also known as glybenclamide)
glyburide micronized
glyburide plus metformin
Glynase
Glynase PresTab
Glyset
Metaglip
metformin
metformin liquid
metformin ER
metformin SR
Micronase
miglitol
nateglinide
pioglitazone
pioglitazone plus glimeperide
pioglitazone plus metformin
pioglitazone plus metformin, extended release
Piomet
Prandimet
Prandin
In addition, any other oral medications prescribed for Type 2 Diabetes not on the list above are included.
Patients taking any of the following medications are not eligible for participation.
- bolus human insulin (Novolin, Humulin)
- rapid acting insulin analogs (Novolog, Humalog, Apidra, Admelog, Humalog 50/50)
- premixed insulins involving long acting and bolus or rapid acting insulin (Insulin Aspart, Insulin isophane, Insulin Lispro, Novolin 70/30, Humulin 70/30, Novolog Mix 70/30, Humalog Mix 75/25, Rhyzodeg, pramlintide)
- inhaled insulin (Afrezza).